reference/8204971

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8204971

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	649
issn	1759-7714 1759-7706
issueIdentifier	5
pageRange	643-649
publicationName	Thoracic Cancer
startingPage	643
bibliographicCitation	Harada D, Isozaki H, Kozuki T, Yokoyama T, Yoshioka H, Bessho A, Hosokawa S, Takata I, Takigawa N, Hotta K, Kiura K; Okayama Lung Cancer Study Group. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. Thorac Cancer. 2021 Mar;12(5):643–9. PMID: 33470536; PMCID: PMC7919114.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6df47b94c9f69266c5cc62c5395bde6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4729fc0b5716e1ced80f46aed5eafea5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_413a9783db866600f225b14e26b59aa7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6955cb3a54e2ea5f757046f8aac25a2b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03fb7f466f4cd479b1601ab188751b31 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1564cfac39cd0712e879f38a82d9254d http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5645-2434 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97c1d181dd52d3078559e08965910690 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9172-9379 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dcc44973bc74c6c9111647667c29a175 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0394-7377 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0112-0843 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8159903b144444074c820c0b1c072dd
date	2021-01-20^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1111/1759-7714.13825 https://pubmed.ncbi.nlm.nih.gov/33470536 https://pubmed.ncbi.nlm.nih.gov/PMC7919114
isPartOf	https://portal.issn.org/resource/ISSN/1759-7714 https://portal.issn.org/resource/ISSN/1759-7706 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43270
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
discusses	http://id.nlm.nih.gov/mesh/M0553416 http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0023875 http://id.nlm.nih.gov/mesh/M0016885 http://id.nlm.nih.gov/mesh/M000599954 http://id.nlm.nih.gov/mesh/M0513130 http://id.nlm.nih.gov/mesh/M0003337
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D002227Q000627 http://id.nlm.nih.gov/mesh/D008175Q000188 http://id.nlm.nih.gov/mesh/D000077547Q000627 http://id.nlm.nih.gov/mesh/D015514Q000378 http://id.nlm.nih.gov/mesh/D010880Q000627 http://id.nlm.nih.gov/mesh/D002289Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D010880Q000494 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D002289Q000473 http://id.nlm.nih.gov/mesh/D047428Q000494 http://id.nlm.nih.gov/mesh/D002227Q000494 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008175Q000473 http://id.nlm.nih.gov/mesh/D000077547Q000494 http://id.nlm.nih.gov/mesh/D000328
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.6.1.1 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b23065537a07b03ba7e2ca1197841172 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_aeebd1980c6662678028fc899ba441eb http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11626560 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7099 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d187535d40b96a60387e8dff44b0c491 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID49806720 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6910 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Showing number of triples: 1 to 70 of 70.